Teladoc Health Inc SEC Filings

Teladoc Health insider plans sale of recently vested shares. A holder of Teladoc Health common stock filed a notice of proposed sale covering 3,897 shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 12/02/2025. These shares were acquired on 12/01/2025 through restricted stock vesting from the issuer as compensation. The filing notes that 177,473,405 shares of Teladoc Health common stock were outstanding. It also reports that the same seller disposed of 3,998 common shares on 09/02/2025 for gross proceeds of $30,326.03. The seller represents that they are not aware of undisclosed material adverse information about the company.

An affiliate of the company with symbol TDOC has filed a Rule 144 notice indicating an intent to sell 4,582 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 34,311.39. The filing notes that 177,473,405 shares of the issuer’s stock were outstanding at the time of the notice; this is a baseline figure, not the amount being sold.

The shares to be sold were acquired on 12/01/2025 via restricted stock vesting from the issuer as compensation, with payment recorded on the same date. The notice also reports that in the past three months, the same seller, identified as Kelly Bliss, sold 4,700 common shares on 09/02/2025 for gross proceeds of 35,650.91.

A shareholder of TDOC has filed a Form 144 notice to sell 2,324 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $17,402.81. The shares are part of a much larger base of 177,473,405 common shares outstanding.

The stock to be sold was acquired on 12/01/2025 through restricted stock vesting from the issuer as compensation. The same seller previously sold 2,383 and 4,149 common shares on 09/02/2025 and 09/03/2025, generating gross proceeds of $18,075.77 and $31,490.91. By signing the notice, the seller represents they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.

Teladoc Health, Inc. director reports open-market stock purchase

A Teladoc Health, Inc. director filed a Form 4 reporting the purchase of 10,000 shares of the company’s common stock. The transaction took place on 11/14/2025 at a price of $6.94 per share, resulting in beneficial ownership of 10,000 shares following the trade, held directly.

The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan that the reporting person adopted on August 15, 2025. Rule 10b5-1 plans are pre-arranged trading programs intended to allow insiders to buy or sell shares according to preset instructions.

Teladoc Health (TDOC): Schedule 13G/A update on ownership

Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen reported beneficial ownership of 5,795,178 Teladoc common shares, representing 3.3% of the class as of September 30, 2025. The filers report shared voting and dispositive power over 5,795,178 shares and no sole voting or dispositive power.

The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of Teladoc. This amendment formalizes current holdings and roles among the reporting persons, including Mr. Cohen’s indirect control of the reporting entities.

Teladoc Health (TDOC) reported Q3 2025 results showing revenue of $626.4 million versus $640.5 million a year ago, reflecting softer BetterHelp contributions partly offset by Integrated Care growth. The company posted a net loss of $49.5 million compared with a $33.3 million loss last year, including a $12.6 million goodwill impairment tied to an Integrated Care acquisition.

For the first nine months, revenue was $1.89 billion versus $1.93 billion, with net loss improving to $175.2 million from $952.8 million due to last year’s large goodwill charge. Q3 segment revenue was $389.5 million for Integrated Care and $236.9 million for BetterHelp. Adjusted EBITDA was $69.9 million, down from $83.3 million.

Cash and equivalents were $726.2 million, supported by operating cash flow of $206.6 million year‑to‑date. Teladoc repaid $550.0 million of Livongo 2025 notes and $0.6 million of 2025 notes; $1.0 billion of 2027 notes remain outstanding. The company established a new $300 million revolving credit facility and had $297.8 million available at quarter end.

Teladoc Health, Inc. furnished an 8‑K to announce it issued a press release with its third‑quarter 2025 financial results. The press release is attached as Exhibit 99.1 and dated October 29, 2025.

The company states the information is being furnished, not filed under the Exchange Act, and therefore is not subject to Section 18 liabilities, nor incorporated into Securities Act filings unless specifically referenced.

Teladoc Health (TDOC) announced preliminary Q3 2025 results, noting they are unaudited and subject to change as the company completes its closing process. The company also stated it continues to expect its consolidated full-year 2025 results to be consistent with the outlook range disclosed on July 29, 2025. A press release with additional details, including non-GAAP measures and reconciliations, was furnished as Exhibit 99.1.

The company also disclosed a leadership change: Chief Financial Officer Mala Murthy informed Teladoc of her resignation effective November 21, 2025. She is expected to present on the company’s third-quarter conference call on October 29, 2025. The company indicated her decision was for personal reasons and not due to any disagreement regarding operations, policies, or practices. The information in the press release and items referenced was furnished, not filed.

Joseph Ronald Catapano, Chief Accounting Officer of Teladoc Health, Inc. (TDOC), reported the vesting and partial sale of restricted stock units. On 10/01/2025 8,333 restricted stock units converted to 8,333 shares of common stock. On 10/02/2025 he sold 2,972 shares at $7.885 per share to cover tax withholding, leaving 5,361 shares beneficially owned following the sale. The filing notes the RSU grant of 25,000 units on 10/01/2024 with one-third vesting on the first anniversary and the remainder vesting in eight substantially equal quarterly installments.